Continuous treatment with a low-dose β-agonist reduces bone mass by increasing bone resorption without suppressing bone formation.
about
Association of polymorphisms in the beta-2 adrenergic receptor gene with fracture risk and bone mineral densityLow dose of propranolol down-modulates bone resorption by inhibiting inflammation and osteoclast differentiation.Clonidine increases bone resorption in humans.Noradrenaline stimulates cell proliferation by suppressing potassium channels via G(i/o) -protein-coupled α(1B) -adrenoceptors in human osteoblasts.Extracellular norepinephrine clearance by the norepinephrine transporter is required for skeletal homeostasis.Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases.The Central Nervous System and Bone Metabolism: An Evolving Story.α1-adrenergic receptor signaling in osteoblasts regulates clock genes and bone morphogenetic protein 4 expression through up-regulation of the transcriptional factor nuclear factor IL-3 (Nfil3)/E4 promoter-binding protein 4 (E4BP4)β-Adrenergic signaling stimulates osteoclastogenesis via reactive oxygen species.β-Adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects.The Interaction between Bmal1 and Per2 in Mouse BMSC Osteogenic Differentiation.Bone Health in Adrenal Disorders.Global Disruption of α2A Adrenoceptor Barely Affects Bone Tissue but Minimizes the Detrimental Effects of Thyrotoxicosis on Cortical Bone
P2860
Q35789214-33B1EA9D-E166-4C09-B5C4-DD5F61BCF42DQ36147294-2030D553-A275-4E61-A1A7-8EAA606158EFQ36620566-7F03386C-E8F3-4327-B3D7-97CA21052F56Q36675825-797F6145-DDF9-4464-8A33-AFD8A8603300Q37233972-4D8D283A-2330-414A-8A23-9C02E6B814FEQ38389210-31904ECA-2C7F-4556-B951-9C8496B4ACF1Q38921950-3EEF5A19-A0D8-4DCD-9D0E-27BB92018A13Q38998700-21FCF844-C865-4626-A4A2-320CF2B7D173Q39241378-E857ACDA-BF4D-4AC0-B4FD-9BB54D46395BQ46214485-C1774ACE-2210-465E-8EA7-ED184240E735Q55030494-64BAE8BF-4ECD-430D-9D66-13E0D0357900Q55088148-E68BBF7F-D61B-445D-BAB5-5AFBEB1135F3Q58697867-7D4BDCCC-ABA9-4DC5-96A0-379383654589
P2860
Continuous treatment with a low-dose β-agonist reduces bone mass by increasing bone resorption without suppressing bone formation.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Continuous treatment with a lo ...... ut suppressing bone formation.
@en
Continuous treatment with a lo ...... ut suppressing bone formation.
@nl
type
label
Continuous treatment with a lo ...... ut suppressing bone formation.
@en
Continuous treatment with a lo ...... ut suppressing bone formation.
@nl
prefLabel
Continuous treatment with a lo ...... ut suppressing bone formation.
@en
Continuous treatment with a lo ...... ut suppressing bone formation.
@nl
P2860
P1476
Continuous treatment with a lo ...... ut suppressing bone formation.
@en
P2093
Akifumi Togari
Hisataka Kondo
P2860
P2888
P356
10.1007/S00223-010-9421-9
P407
P577
2010-09-30T00:00:00Z